Morbid obesity is adversely associated with perioperative outcomes inpatients undergoing robot-assisted laparoscopic radical prostatectomyShow others and affiliations
2020 (English)In: Canadian Urological Association Journal (CUAJ), ISSN 1911-6470, Vol. 14, no 11, p. E574-E581Article in journal (Refereed) Published
Abstract [en]
Introduction: Robot-assisted laparoscopic radical prostatectomy (RALRP) may be more challenging in obese individuals. This study aimed to evaluate whether obesity had an adverse effect on perioperative outcomes following RALRP.
Methods: Hospitalized patients who underwent RAL-RP from 2008-2014 were identified using the National Inpatient Sample database. We grouped RALRP patients into non-obese, obesity class I-II, and obesity class III (morbid obesity). Rates of blood transfusion, intraoperative and postoperative complications, in-hospital mortality, prolonged length of stay, and total costs were compared among the three groups by univariate regression, multivariate regression, and propensity score weighting analysis.
Results: Of 53 301 patients identified, 48 725 were non-obese, 3572 were diagnosed with obesity class I-II, and 1004 were diagnosed with morbid obesity. Compared to non-obesity (7.62%), overall postoperative complications were commonly observed in obesity class I-II (10.55%) and morbid obesity (17.11%). Multivariable analyses suggested that morbid obesity was associated with increased overall postoperative (odds ratio PRI 2.00, 95% confidence interval [CI] 1.65-2.42), cardiac (OR 1.63, 95% CI 1.03-2.58), respiratory (OR 4.03, 95% CI 3.04-5.36), genitourinary (OR 1.77, 95% CI 1.08-2.90), miscellaneous medical (OR 1.94, 95% CI 1.58-2.39) complications, prolonged hospitalization (OR 1.86, 95% CI 1.57-2.21), arid 12% higher total cost. Propensity score weighting analysis yielded similar results. Adequate covariate balance was achieved for all variables after weighting.
Conclusions: Morbid obesity is adversely associated with perioperative outcomes in RALRP Close management is required in patients undergoing RALRP with morbid obesity for potential worse prognosis.
Place, publisher, year, edition, pages
Canadian Medical Association , 2020. Vol. 14, no 11, p. E574-E581
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:oru:diva-87771DOI: 10.5489/cuaj.6389ISI: 000588327500008PubMedID: 32520702Scopus ID: 2-s2.0-85089919502OAI: oai:DiVA.org:oru-87771DiVA, id: diva2:1506441
Note
Funding Agencies:
National Key Research and Development Program of China 2017YFC0908005
National Thirteenth Five-Year Plan Major Special Project 2017ZX09304016
Precision Good Clinical Practice Center for Novel Drugs of Tumor and Diseases of Genitourinary System 2017ZX09304030
2020-12-032020-12-032025-02-18Bibliographically approved